These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 20426951)

  • 1. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
    Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
    Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
    BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical significance of sequential monitoring minimal residual disease in childhood B-cell acute lymphoblastic leukemia].
    Wang L; Jiang H; Li H; Shao JB; Lu ZH; Yang JW; Yang WQ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jun; 32(6):400-3. PubMed ID: 21781499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical Significance of Minimal Residual Disease in Risk Stratification and Prognosis of Childhood B-lineage Acute Lymphoblastic Leukemia].
    An FY; Zhang SH; Kong LJ; Liang Y; Xu JX; He HL; Chai YH; Zhao WL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):729-735. PubMed ID: 28641626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
    Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
    J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
    Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
    Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of early treatment response in children with acute lymphoblastic leukemia: a single institution experience in Shanghai, China.
    Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jan; 11(1):5-9. PubMed ID: 19149913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
    Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H
    Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
    Balduzzi A; Di Maio L; Silvestri D; Songia S; Bonanomi S; Rovelli A; Conter V; Biondi A; Cazzaniga G; Valsecchi MG
    Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term outcome of childhood T-cell acute lymphoblastic leukemia treated with modified national protocol of childhood leukemia in China-acute lymphoblastic leukemia 2008].
    Liao C; Shen DY; Xu XJ; Xu WQ; Zhang JY; Song H; Yang SL; Zhao FY; Shen HP; Tang YM
    Zhonghua Er Ke Za Zhi; 2020 Sep; 58(9):758-763. PubMed ID: 32872717
    [No Abstract]   [Full Text] [Related]  

  • 14. [Multicenter evaluation of minimal residual disease monitoring in early induction therapy for treatment of childhood acute lymphoblastic leukemia].
    Wu XJ; Liao N; Mai HR; Li XY; Wan WQ; Yang LH; Huang LB; Luo XQ; Tian C; Chen QW; Long XJ; He YY; Wang Y; Li ZG; Xu HG
    Zhonghua Er Ke Za Zhi; 2024 Mar; 62(4):337-344. PubMed ID: 38527504
    [No Abstract]   [Full Text] [Related]  

  • 15. [Evaluation on protocol SCMS-ALL-2005 for childhood B lineage acute lymphoblastic leukemia].
    Tang JY; Xue HL; Chen J; Pan C; Li BS; Gu LJ; Dong L; Hu WT; Shen SH; Zhou M; Ye QD; Jiang H; Luo CY
    Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):546-50. PubMed ID: 22490159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
    ; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
    J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical value of minimal residual disease detection by flow cytometry in childhood B-cell acute lymphoblastic leukemia].
    Chang L; Zhang G; Shi H; Ye L; Jiang YM
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Dec; 16(12):1245-9. PubMed ID: 25523574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Day 22 of induction therapy is important for minimal residual disease assessment by flow cytometry in childhood acute lymphoblastic leukemia.
    Xu XJ; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Xu WQ
    Leuk Res; 2012 Aug; 36(8):1022-7. PubMed ID: 22483330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.